 Shelley Crary
Concepts (163)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 8 | 2024 | 102 | 4.080 |
Why?
| | Blood Coagulation Disorders | 4 | 2022 | 38 | 2.690 |
Why?
| | Kasabach-Merritt Syndrome | 3 | 2024 | 5 | 1.980 |
Why?
| | Splenectomy | 10 | 2018 | 34 | 1.700 |
Why?
| | Hemostasis | 2 | 2024 | 59 | 1.600 |
Why?
| | Spherocytosis, Hereditary | 6 | 2015 | 14 | 1.490 |
Why?
| | Sclerotherapy | 3 | 2022 | 46 | 1.460 |
Why?
| | Hemangioendothelioma | 3 | 2024 | 8 | 1.270 |
Why?
| | Hemophilia A | 2 | 2024 | 25 | 0.990 |
Why?
| | Sarcoma, Kaposi | 2 | 2023 | 75 | 0.950 |
Why?
| | Anticoagulants | 3 | 2024 | 256 | 0.930 |
Why?
| | Child | 27 | 2024 | 6906 | 0.850 |
Why?
| | Thrombosis | 2 | 2024 | 250 | 0.820 |
Why?
| | Child, Preschool | 20 | 2024 | 3942 | 0.790 |
Why?
| | Thrombelastography | 1 | 2020 | 25 | 0.710 |
Why?
| | Anemia, Sickle Cell | 5 | 2021 | 94 | 0.690 |
Why?
| | Sirolimus | 2 | 2023 | 62 | 0.680 |
Why?
| | Bleomycin | 2 | 2022 | 34 | 0.640 |
Why?
| | Adolescent | 21 | 2024 | 6443 | 0.630 |
Why?
| | Autoimmune Lymphoproliferative Syndrome | 1 | 2018 | 2 | 0.610 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 77 | 0.560 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 3 | 2024 | 24 | 0.540 |
Why?
| | Young Adult | 12 | 2024 | 4102 | 0.530 |
Why?
| | Humans | 38 | 2024 | 50503 | 0.500 |
Why?
| | Postoperative Complications | 3 | 2014 | 1033 | 0.500 |
Why?
| | Hematinics | 2 | 2013 | 13 | 0.470 |
Why?
| | Reticulocyte Count | 2 | 2015 | 5 | 0.470 |
Why?
| | Anemia, Iron-Deficiency | 2 | 2013 | 18 | 0.470 |
Why?
| | Female | 23 | 2024 | 27081 | 0.460 |
Why?
| | Hemorrhage | 4 | 2024 | 197 | 0.450 |
Why?
| | Factor IX | 2 | 2024 | 2 | 0.450 |
Why?
| | Hemophilia B | 2 | 2024 | 5 | 0.450 |
Why?
| | Male | 23 | 2024 | 25907 | 0.450 |
Why?
| | Heart Transplantation | 1 | 2018 | 363 | 0.450 |
Why?
| | Adult | 13 | 2024 | 13577 | 0.420 |
Why?
| | Infant | 12 | 2024 | 3628 | 0.410 |
Why?
| | Genetic Therapy | 2 | 2024 | 120 | 0.410 |
Why?
| | Hematologic Diseases | 2 | 2009 | 21 | 0.410 |
Why?
| | Ferric Compounds | 1 | 2010 | 11 | 0.360 |
Why?
| | Retrospective Studies | 11 | 2024 | 6263 | 0.350 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 124 | 0.330 |
Why?
| | Vascular Diseases | 2 | 2009 | 73 | 0.320 |
Why?
| | Blood Flow Velocity | 2 | 2020 | 99 | 0.320 |
Why?
| | Enoxaparin | 1 | 2008 | 31 | 0.310 |
Why?
| | Thromboembolism | 1 | 2006 | 55 | 0.260 |
Why?
| | Venous Thrombosis | 1 | 2006 | 87 | 0.250 |
Why?
| | Risk Factors | 5 | 2024 | 3724 | 0.240 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 461 | 0.240 |
Why?
| | Osteomyelitis | 1 | 2006 | 128 | 0.240 |
Why?
| | Prospective Studies | 6 | 2023 | 2378 | 0.230 |
Why?
| | Hematology | 1 | 2024 | 27 | 0.230 |
Why?
| | Hemoglobins | 4 | 2015 | 109 | 0.230 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 52 | 0.230 |
Why?
| | Professional Role | 1 | 2024 | 77 | 0.230 |
Why?
| | Factor VIII | 1 | 2024 | 23 | 0.230 |
Why?
| | von Willebrand Diseases | 1 | 2024 | 22 | 0.220 |
Why?
| | Vascular Neoplasms | 1 | 2023 | 17 | 0.220 |
Why?
| | Treatment Outcome | 6 | 2024 | 5283 | 0.220 |
Why?
| | Administration, Oral | 2 | 2018 | 434 | 0.220 |
Why?
| | Anemia, Hemolytic, Congenital | 2 | 2014 | 4 | 0.220 |
Why?
| | Autoantibodies | 1 | 2024 | 117 | 0.220 |
Why?
| | Critical Illness | 2 | 2020 | 302 | 0.210 |
Why?
| | Hemangioma | 1 | 2023 | 83 | 0.200 |
Why?
| | Middle Aged | 8 | 2024 | 12611 | 0.200 |
Why?
| | Databases, Factual | 2 | 2024 | 673 | 0.190 |
Why?
| | Pupil | 1 | 2021 | 29 | 0.190 |
Why?
| | Acute Pain | 1 | 2021 | 11 | 0.190 |
Why?
| | Anxiety | 1 | 2024 | 285 | 0.190 |
Why?
| | Mental Health | 1 | 2024 | 228 | 0.190 |
Why?
| | Infusions, Intravenous | 3 | 2013 | 213 | 0.190 |
Why?
| | Arterial Occlusive Diseases | 1 | 2021 | 79 | 0.180 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 20 | 0.180 |
Why?
| | Multiple Organ Failure | 1 | 2020 | 48 | 0.170 |
Why?
| | Blood Coagulation | 1 | 2020 | 60 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 226 | 0.170 |
Why?
| | Klippel-Trenaunay-Weber Syndrome | 1 | 2019 | 3 | 0.160 |
Why?
| | Receptors, Fc | 1 | 2019 | 8 | 0.160 |
Why?
| | Thrombopoietin | 1 | 2019 | 9 | 0.160 |
Why?
| | Pain | 2 | 2021 | 387 | 0.160 |
Why?
| | Vitiligo | 1 | 2019 | 8 | 0.160 |
Why?
| | Leukoencephalopathies | 1 | 2019 | 14 | 0.160 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2019 | 9 | 0.160 |
Why?
| | Depression | 1 | 2024 | 582 | 0.160 |
Why?
| | Nervous System Malformations | 1 | 2019 | 17 | 0.160 |
Why?
| | Alopecia | 1 | 2019 | 29 | 0.160 |
Why?
| | Recombinant Fusion Proteins | 1 | 2019 | 179 | 0.150 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2018 | 10 | 0.150 |
Why?
| | Skin Neoplasms | 1 | 2023 | 491 | 0.150 |
Why?
| | Fibrinogen | 1 | 2018 | 32 | 0.150 |
Why?
| | Bilirubin | 3 | 2015 | 40 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2019 | 81 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 79 | 0.150 |
Why?
| | Follow-Up Studies | 2 | 2021 | 2242 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2011 | 1610 | 0.130 |
Why?
| | Aged | 5 | 2024 | 9741 | 0.130 |
Why?
| | Hydroxyurea | 1 | 2015 | 29 | 0.120 |
Why?
| | Ankyrins | 1 | 2014 | 9 | 0.120 |
Why?
| | Prevalence | 2 | 2024 | 971 | 0.120 |
Why?
| | Acute Chest Syndrome | 1 | 2014 | 8 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1033 | 0.120 |
Why?
| | Platelet Count | 2 | 2019 | 65 | 0.110 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 78 | 0.110 |
Why?
| | Iron-Dextran Complex | 1 | 2013 | 2 | 0.110 |
Why?
| | Quality of Life | 1 | 2019 | 851 | 0.100 |
Why?
| | Hematoma | 1 | 2013 | 64 | 0.100 |
Why?
| | Protein Precursors | 1 | 2011 | 43 | 0.100 |
Why?
| | Remission, Spontaneous | 1 | 2011 | 24 | 0.090 |
Why?
| | Anemia, Hemolytic | 1 | 2011 | 10 | 0.090 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2011 | 29 | 0.090 |
Why?
| | Tricuspid Valve | 1 | 2011 | 23 | 0.090 |
Why?
| | Texas | 1 | 2011 | 142 | 0.090 |
Why?
| | Early Diagnosis | 1 | 2011 | 88 | 0.090 |
Why?
| | Glucaric Acid | 1 | 2010 | 1 | 0.090 |
Why?
| | Infant, Newborn | 3 | 2024 | 2749 | 0.090 |
Why?
| | Blood Cell Count | 1 | 2010 | 39 | 0.090 |
Why?
| | Aged, 80 and over | 2 | 2024 | 3226 | 0.090 |
Why?
| | Cholesterol, LDL | 1 | 2010 | 41 | 0.090 |
Why?
| | Lipids | 1 | 2010 | 152 | 0.080 |
Why?
| | C-Reactive Protein | 1 | 2010 | 144 | 0.080 |
Why?
| | Ultrasonography | 1 | 2011 | 435 | 0.080 |
Why?
| | Neoplasms | 1 | 2019 | 1251 | 0.080 |
Why?
| | Medical Audit | 1 | 2008 | 21 | 0.080 |
Why?
| | Time Factors | 3 | 2024 | 2935 | 0.080 |
Why?
| | Cholesterol | 1 | 2007 | 150 | 0.070 |
Why?
| | Acute Disease | 1 | 2006 | 373 | 0.060 |
Why?
| | Terminology as Topic | 1 | 2024 | 67 | 0.060 |
Why?
| | Vincristine | 1 | 2023 | 82 | 0.050 |
Why?
| | Disease Management | 1 | 2024 | 178 | 0.050 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 120 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2023 | 128 | 0.050 |
Why?
| | Alleles | 1 | 2023 | 256 | 0.050 |
Why?
| | Genetic Testing | 1 | 2023 | 120 | 0.050 |
Why?
| | Sclerosing Solutions | 1 | 2022 | 15 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 230 | 0.050 |
Why?
| | Registries | 2 | 2015 | 563 | 0.050 |
Why?
| | P-Selectin | 1 | 2021 | 32 | 0.050 |
Why?
| | Analgesics | 1 | 2021 | 116 | 0.040 |
Why?
| | Pain Measurement | 1 | 2021 | 270 | 0.040 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2020 | 174 | 0.040 |
Why?
| | United States | 2 | 2024 | 4955 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2019 | 88 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 486 | 0.040 |
Why?
| | Incidence | 1 | 2021 | 1032 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2019 | 444 | 0.040 |
Why?
| | Length of Stay | 1 | 2020 | 629 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 909 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2018 | 225 | 0.030 |
Why?
| | Therapeutic Equivalency | 1 | 2015 | 7 | 0.030 |
Why?
| | Solutions | 1 | 2015 | 25 | 0.030 |
Why?
| | Capsules | 1 | 2015 | 28 | 0.030 |
Why?
| | Antisickling Agents | 1 | 2015 | 13 | 0.030 |
Why?
| | Decision Making | 1 | 2018 | 272 | 0.030 |
Why?
| | Reticulocytes | 1 | 2014 | 6 | 0.030 |
Why?
| | Physicians | 1 | 2018 | 232 | 0.030 |
Why?
| | Risk Assessment | 1 | 2019 | 1270 | 0.030 |
Why?
| | Forehead | 1 | 2013 | 8 | 0.030 |
Why?
| | Laparoscopy | 1 | 2015 | 173 | 0.030 |
Why?
| | Molecular Weight | 1 | 2013 | 82 | 0.030 |
Why?
| | Syndrome | 1 | 2011 | 240 | 0.020 |
Why?
| | Hemolysis | 1 | 2009 | 28 | 0.020 |
Why?
| | Thrombocytosis | 1 | 2007 | 4 | 0.020 |
Why?
| | Polycythemia | 1 | 2007 | 9 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2009 | 287 | 0.020 |
Why?
|
|
Crary's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|